213190-12-6

Basic information

• Product Name: 4-bromo-2-fluoro-N-methylaniline
• Synonyms: 4-bromo-2-fluoro-N-methylaniline;BENZENAMINE,4-BROMO-2-FLUORO-N-METHYL-
• CAS NO: 213190-12-6
• Molecular Formula: C₇H₇BrFN
• Molecular Weight: 204.04
• Mol File: 213190-12-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-bromo-2-fluoro-N-methylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-2-fluoro-N-methylaniline(213190-12-6)
• EPA Substance Registry System: 4-bromo-2-fluoro-N-methylaniline(213190-12-6)

Safety Data

• Hazardous Substances Data: 213190-12-6(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 367-24-8 4-bromo-2-fluoroaniline 
• 13061-96-6 dihydroxy-methyl-borane 
• 209958-42-9 tert-butyl N-(4-bromo-2-fluorophenyl)carbamate 
• 67-56-1 methanol 

Downstream Products

• 173607-64-2 N-methyl-N-trifluoromethyl-4-bromo-2-fluoroaniline 
• 1246093-93-5 2-fluoro-N-methyl-4-((trimethylsilyl)ethynyl)aniline 
• 1246091-94-0 2-((3-fluoro-4-(methylamino)phenyl)ethynyl)benzo[d]thiazol-6-ol 
• 1246091-95-1 2-fluoro-4-((5-methoxythiazolo[5,4-b]pyridin-2-yl)ethynyl)-N-methylaniline 
• 1246093-94-6 4-ethynyl-2-fluoro-N-methylaniline 
• 1246093-95-7 2-fluoro-4-((6-methoxybenzo[d]thiazol-2-yl)ethynyl)-N-methylaniline 
• 637003-10-2 2-(3-fluoro-4-(methylamino)phenyl)benzo[d]thiazol-6-ol 

Relevant articles and documents

Method for realizing N-alkylation by using alcohols as carbon source under photocatalysis

The invention discloses a method for realizing N-alkylation by using alcohols as a carbon source under photocatalysis, and belongs to the technical field of catalytic synthesis. Alcohol, a substrate raw material and a catalyst are placed in a reaction device, ultraviolet and/or visible light irradiation is carried out in an inert atmosphere, after the irradiation is finished, solid-liquid separation is carried out to remove the catalyst, and an N-alkylation product can be obtained through extraction, distillation and purification, wherein the substrate raw material comprises any one of an amine compound, an aromatic nitro compound or an aromatic nitrile compound, the alcohol comprises any one or more of soluble primary alcohols, and the catalyst is metal oxide/titanium dioxide or metal sulfide/titanium dioxide. The method is simple and easy to operate, can be used for efficient photocatalysis one-pot multi-step hydrogenation N-alkylation reaction, and is mild in reaction condition, high in chemical selectivity of N-alkylamine, good in catalyst stability and easy to recycle.

Derisking the Cu-Mediated 18F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands

Molecules labeled with fluorine-18 (18F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using the copper-mediated 18F-fluorination of aryl boron reagents with 18F-fluoride as a model reaction. This approach is based on a study examining how the presence of heterocycles commonly used in drug development affects the efficiency of 18F-fluorination for a representative aryl boron reagent, and on the labeling of more than 50 (hetero)aryl boronic esters. This set of data allows for the application of this derisking strategy to the successful radiosynthesis of seven structurally complex pharmaceutically relevant heterocycle-containing molecules.

Imaging agents for detecting neurological disorders

Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.